Glucotrack reports Q3 net loss of $4.2M; cash $7.9M to fund through Q1 2026; IDE submission Spring 2026

Glucotrack, Inc.

2025-Q3 EPS reported $30.09

Q3 2025 net loss $4.2M ($4.64 per share) vs $5.1M in Q3 2024; nine-month net loss $15.8M.
Cash and equivalents $7.9M at Sep 30, 2025; expected to fund operations through first quarter 2026.
Secured $3M convertible note ($3.6M principal) and $20M ELOC; proceeds to repay note and eliminate warrant dilution.
IDE submission for CBGM to FDA expected Spring 2026; long-term feasibility study initiated in Australia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.